Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PalinGen is a chorion-free human amniotic membrane allograft developed by Amnio Technology. It is processed from healthy amniotic tissue using the proprietary Advantek process, which excludes the chorion layer to minimize the potential for graft-versus-host autoimmune responses. PalinGen functions as a biological wound covering and physical barrier that provides structural support for native tissues, mimicking the protective role of the amniotic membrane during pregnancy. The allograft contains naturally occurring collagen substrates, growth factors, extracellular matrix proteins, cytokines, and regulatory proteins that facilitate the complex biological processes involved in wound healing. It is indicated for the treatment of full and partial-thickness, acute, and chronic wounds, as well as complex surgical wounds and burns.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PalinGen.